Ani Pharmaceuticals (ANIP) Invested Capital (2010 - 2026)

Ani Pharmaceuticals has disclosed Invested Capital across 17 years of filings, most recently posting $898.7 million for Q2 2026.

• In Q2 2026, Invested Capital rose 19.59% year-over-year to $898.7 million; the TTM figure through Jun 2026 stood at $898.7 million (up 19.59% YoY), while the FY2025 annual figure was $849.8 million, up 17.71% from the prior year.
• Invested Capital came in at $898.7 million for Q2 2026 at Ani Pharmaceuticals, up from $867.6 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $898.7 million in Q2 2026 to a low of $623.4 million in Q3 2022.
• Average Invested Capital over 5 years is $732.8 million, with a median of $732.5 million recorded in 2023.
• The largest YoY upside for Invested Capital was 63.57% in 2022 against a maximum downside of 3.26% in 2022.
• Over 5 years, Invested Capital stood at $625.1 million in 2022, then gained by 16.76% to $729.8 million in 2023, then slipped by 1.08% to $722.0 million in 2024, then rose by 17.71% to $849.8 million in 2025, then advanced by 5.75% to $898.7 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $898.7 million in Q2 2026, $867.6 million in Q1 2026, and $849.8 million in Q4 2025.